EUVIMEDOpdag EUVIMED
Crossref

Single‐atom Pt‐N‐C nanozyme targets Rara/Wnt/β‐catenin axis for diabetic cardiomyopathy treatment

Lina Hao iD, Xiufen Qu iD

British Journal of Pharmacology · 2026-12 · 183 (23) · 6903-6926

DOI: 10.1111/bph.70633 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-08-24. Written by Lina Hao and 1 co-authors. Institution: Department of Cardiovascular Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Major MEDLINE topics: Diabetic Cardiomyopathies, Wnt Signaling Pathway, Tretinoin. 51 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Diabetic cardiomyopathy (DCM) lacks effective therapies because of complex mechanisms. This study aims to develop a single‐atom nanozyme for integrated antioxidant and signalling regulation in DCM. Experimental Approach A graphene quantum dot‐templated single‐atom Pt‐N‐C nanozyme (PtsaN‐C) was synthesised for all‐trans retinoic acid (ATRA) delivery (PtsaN‐C@ATRA). In vitro antioxidant activity and in vivo efficacy were evaluated in DCM mice, combined with scRNA‐seq for mechanistic analysis. Key Results PtsaN‐C@ATRA improved cardiac function, reduced fibrosis/apoptosis and activated the Rara/Wnt/β‐catenin axis to promote cardiomyocyte differentiation. Conclusions and Implications PtsaN‐C@ATRA represents a novel strategy merging nanozyme catalysis with transcriptional regulation, offering potential for clinical translation in DCM.

Subjects

MeSH terms (MEDLINE)

Diabetic CardiomyopathiesWnt Signaling PathwayTretinoinAnimalsMicebeta CateninAntioxidantsMyocytes, CardiacQuantum DotsHumans

Author keywords

Rara/Wnt/β‐catenin signalling axisall‐trans retinoic acidantioxidantcardiomyocyte differentiationdiabetic cardiomyopathysingle‐atom Pt‐N‐C nanozyme

Substances

Tretinoinbeta CateninAntioxidants

Authors and institutions

  • Department of Cardiovascular Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

ORCID profiles: Lina Hao, Xiufen Qu

Cite

APA

Hao, L., & Qu, X. (2026). Single‐atom Pt‐N‐C nanozyme targets Rara/Wnt/β‐catenin axis for diabetic cardiomyopathy treatment. British Journal of Pharmacology, 183(23), 6903-6926. https://doi.org/10.1111/bph.70633

Vancouver

Hao L, Qu X. Single‐atom Pt‐N‐C nanozyme targets Rara/Wnt/β‐catenin axis for diabetic cardiomyopathy treatment. British Journal of Pharmacology. 2026;183(23):6903-6926. doi:10.1111/bph.70633

BibTeX
@article{Hao2026,
  author = {Hao, Lina and Qu, Xiufen},
  title = {Single‐atom Pt‐N‐C nanozyme targets Rara/Wnt/β‐catenin axis for diabetic cardiomyopathy treatment},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {23},
  pages = {6903--6926},
  doi = {10.1111/bph.70633}
}
Start for free →